title: A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue.
abstract: OBJECTIVE
  To test the antitumour effect of gonadotrophin releasing-hormone (GnRH) analogues in women with recurrent endometrial cancer.
  
  
  METHODS
  An open phase II observational trial of GnRH analogues. Serial measurements of gonadotrophins, sex hormones and tumour dimensions were made together with repeat biopsy when possible to assess the response to treatment.
  
  
  METHODS
  The outpatient clinics of the Department of Medical Oncology at The Royal London, Royal Marsden and St Bartholomew's hospitals.
  
  
  METHODS
  17 patients with endometrial cancer which had recurred after surgery, radiotherapy and progesterone treatment and was symptomatic, progressive and assessable for response.
  
  
  METHODS
  Monthly subcutaneous injection of GnRH analogue.
  
  
  METHODS
  Reduction in serum gonadotrophins and reduction in tumour dimensions.
  
  
  RESULTS
  Six out of 17 patients (35%, 95% CI 12.6-58%) achieved a complete or partial remission which continues for a median of 20 months with no adverse effects.
  
  
  CONCLUSIONS
  GnRH analogues have a significant antitumour effect in recurrent endometrial cancer which warrants further examination in comparison with progestogens.
authors.affiliation: Department of Medical Oncology, Royal London Hospital.
authors.forename: C J
authors.initials: CJ
authors.lastname: Gallagher
authors.forename: R T
authors.initials: RT
authors.lastname: Oliver
authors.forename: D H
authors.initials: DH
authors.lastname: Oram
authors.forename: C G
authors.initials: CG
authors.lastname: Fowler
authors.forename: P R
authors.initials: PR
authors.lastname: Blake
authors.forename: B S
authors.initials: BS
authors.lastname: Mantell
authors.forename: M L
authors.initials: ML
authors.lastname: Slevin
authors.forename: H F
authors.initials: HF
authors.lastname: Hope-Stone
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D008875:Middle Aged; D011379:Prognosis
chemical_list: D007987:Gonadotropin-Releasing Hormone